Envonalkib citrate
Modify Date: 2025-09-18 19:42:56
Envonalkib citrate structure
|
Common Name | Envonalkib citrate | ||
|---|---|---|---|---|
| CAS Number | 1867204-56-5 | Molecular Weight | 698.52 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C30H34Cl2FN5O9 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Envonalkib citrateEnvonalkib citrate is a potent and orally active inhibitor of ALK, with IC50s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib citrate can be used for the research of non-small cell lung cancer[1]. |
| Name | Envonalkib citrate |
|---|
| Description | Envonalkib citrate is a potent and orally active inhibitor of ALK, with IC50s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib citrate can be used for the research of non-small cell lung cancer[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 1.96 nM (WT-ALK), 35.1 nM (mutated L1196M-ALK), 61.3 nM (mutated G1269S-ALK)[1] |
| In Vivo | Envonalkib citrate (formula I) (12.5-25 mg/kg; p.o. once daily for 14 days) inhibits the growth of human non-small cell lung cancer NCI-H2228 nude mice xenografts[1]. |
| References |
[1]. Feng G, et, al. Pyridine-substituted 2-aminopyridine protein kinase inhibitors. WO2016015676A1. |
| Molecular Formula | C30H34Cl2FN5O9 |
|---|---|
| Molecular Weight | 698.52 |